A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
By participating in PRIMA, you are helping to advance our knowledge of cancer and, we hope, improve care for people who are affected by ovarian cancer.
The PRIMA clinical trial is being done to find out if niraparib, a type of PARP inhibitor, can help delay the worsening of ovarian, peritoneal, or fallopian tube cancer among patients who have been previously treated with a platinum-based therapy. (Potential participants will have their tumor tested first, at no cost, to see if PRIMA is a good fit for them.)
Niraparib is a PARP inhibitor. PARP inhibitors are a class of medications that were found in studies to be effective against recurrent ovarian cancer. PARP inhibitors block an enzyme used by cancer cells to repair breaks in their DNA. When they can’t mend their DNA, the cancer cells die.
To learn more about PARP inhibitors, click here.
About 468 people will participate in the clinical research trial. Two out of three will receive the study medication (the PARP inhibitor, niraparib), and one out of three will receive a placebo. Neither the participants nor their doctors will know who is and is not receiving the study medication. Participants will take up to three pills once a day. Treatment will continue until the disease progresses or the participant chooses to discontinue.
When you participate in a clinical research trial, you are playing an important role in advancing science that can result in effective treatments for individuals like you who are affected by ovarian cancer.
For more information on the PRIMA clinical research trial, please contact a research site near you.